Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8212MR)

This product GTTS-WQ8212MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8212MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6628MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ10824MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ854MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ1092MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ3803MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ4942MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ14042MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ7091MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW